NATALEE (TRIO033) Phase III trial demonstrates ribociclib significantly reduces the risk of recurrence for patients with early breast cancer, at interim analysis
EDMONTON, Alberta, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Translational Research in Oncology (TRIO), a global academic clinical research organization, announced today enrolment of first patient in the LidERA Breast Cancer (TRIO045) trial, a Phase 3 randomized, multi-center, open-label global clinical trial of adjuvant endocrine therapy, giredestrant (GDC-9545) sponsored by F. Hoffmann-LaRoche.